Investor Relations Contact:
Anacor is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule therapeutics derived from its novel boron chemistry platform. We currently have five product candidates in clinical development. Our three lead product candidates include two topically administered dermatologic compounds— tavaborole (formerly AN2690) , an antifungal for the treatment of onychomycosis, and AN2728, an anti-inflammatory for the treatment of psoriasis, as well as a systemic antibiotic for the treatment of infections caused by Gram-negative bacteria—GSK2251052, or GSK '052 (formerly referred to as AN3365). In addition, we are developing AN2718 as a topical antifungal product candidate for the treatment of onychomycosis and skin fungal infections, and AN2898 as a topical anti-inflammatory product candidate for the treatment of psoriasis and atopic dermatitis. We have entered into and are seeking partnerships to expand the therapeutic application and commercial value of our boron chemistry platform.
Mar 31, 2014
Anacor Pharmaceuticals Announces First Patient Enrolled in Phase 3 Trial of AN2728 in Mild-to-Moderate Atopic Dermatitis
Mar 19, 2014
Anacor Pharmaceuticals Appoints Paul L. Berns as Chief Executive Officer
View all »Events & Presentations
Mar 13, 2014 at 2:00 PM PT
Anacor Fourth Quarter 2013 Financial Results Conference Call
Mar 3, 2014 at 3:30 PM ET
Cowen & Company 34th Annual Health Care Conference
Receive Email Alerts
Sign up to receive e-mail alerts
whenever Anacor posts new information to the site.